What Drugs Should You Not Take With Rivaroxaban? The Complete Interaction Guide

Rivaroxaban (Xarelto) is a direct factor Xa inhibitor used to prevent blood clots, but it has critical interactions with dozens of common medications. Combined P-glycoprotein and CYP3A4 inhibitors like ketoconazole can nearly double rivaroxaban blood levels and dramatically increase bleeding risk, while strong enzyme inducers like rifampin can reduce drug effectiveness and cause dangerous blood clots. Never combine rivaroxaban with other anticoagulants (warfarin, enoxaparin) unless specifically directed by your cardiologist, and always inform your doctor and pharmacist of every medication, supplement, and herbal product you take.

What Rivaroxaban Is and How It Works

Rivaroxaban is an oral anticoagulant belonging to the class of direct factor Xa inhibitors. It works by selectively blocking factor Xa, a crucial enzyme in the coagulation cascade responsible for converting prothrombin to thrombin. By inhibiting this step, rivaroxaban prevents the formation of blood clots. It is prescribed for multiple indications: atrial fibrillation (to reduce stroke risk), deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment and prevention, and acute coronary syndrome.

Unlike older anticoagulants such as warfarin, rivaroxaban does not require regular blood test monitoring (INR testing), making it appealing for many patients. However, this convenience comes with a critical caveat: the drug's blood levels are highly dependent on two major drug-metabolizing systems—the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. These are the gateways controlling how much rivaroxaban enters and leaves your body. When other medications inhibit or induce these systems, rivaroxaban exposure can change dramatically, altering its safety and efficacy in unpredictable ways.

The FDA's prescribing information emphasizes that rivaroxaban undergoes significant hepatic metabolism via CYP3A4, CYP2J2, and CYP-independent mechanisms. Additionally, P-glycoprotein actively pumps rivaroxaban out of the body. Any drug that disrupts either pathway can cause serious harm: too much rivaroxaban leads to bleeding; too little leads to clot formation.

How Rivaroxaban Interactions Occur: The Pharmacological Mechanism

Understanding rivaroxaban interactions requires knowledge of two cellular gatekeepers: CYP3A4 and P-glycoprotein.

CYP3A4 is a liver enzyme responsible for metabolizing roughly 50% of all drugs on the market. It breaks down rivaroxaban into inactive metabolites that are then eliminated. When a second drug inhibits CYP3A4, rivaroxaban accumulates in the bloodstream because it is metabolized more slowly. Conversely, when a drug induces (activates) CYP3A4, rivaroxaban is metabolized faster, and blood levels drop.

P-glycoprotein (MDR1 transporter) is a membrane protein that actively pumps xenobiotics (foreign substances, including drugs) out of cells and into the bloodstream for elimination. P-glycoprotein works synergistically with CYP3A4—they share many common inhibitors and inducers. When P-glycoprotein is inhibited, rivaroxaban cannot be efficiently removed from intestinal cells and liver cells, so it accumulates. When P-glycoprotein is induced, rivaroxaban is rapidly expelled, reducing exposure.

The most dangerous interactions occur with drugs that are combined CYP3A4 and P-gp inhibitors (like ketoconazole or ritonavir) or combined inducers (like rifampin or carbamazepine). Dual pathway inhibition or induction produces multiplicative changes in drug exposure—sometimes 2- to 3-fold increases or decreases in blood levels.

Contraindicated Interactions: Drugs That Must Be Avoided With Rivaroxaban

1. Ketoconazole and Other Strong CYP3A4/P-gp Inhibitors

Ketoconazole (and other azole antifungals like itraconazole and voriconazole) is a potent dual inhibitor of CYP3A4 and P-glycoprotein. Clinical studies have shown that ketoconazole increases rivaroxaban exposure by up to 160%, effectively giving patients a rivaroxaban overdose. This dramatically increases bleeding risk.

The FDA labeling explicitly states that rivaroxaban should not be used with ketoconazole. The same recommendation applies to ritonavir (a protease inhibitor used in HIV treatment and as a pharmacokinetic booster in other antivirals). Ritonavir is one of the most potent CYP3A4 inhibitors known, and concurrent use with rivaroxaban is contraindicated.

Other azole antifungals (itraconazole, voriconazole) carry similar contraindications. Additionally, macrolide antibiotics like clarithromycin and azithromycin are moderate-to-strong CYP3A4 inhibitors and warrant avoidance or careful monitoring with dose adjustments.

2. Rifampin, Carbamazepine, Phenytoin, and Other Strong CYP3A4/P-gp Inducers

These drugs do the opposite: they rev up CYP3A4 and P-glycoprotein, causing rivaroxaban to be metabolized and eliminated so quickly that therapeutic blood levels cannot be maintained. Rifampin (a tuberculosis antibiotic) decreases rivaroxaban exposure by approximately 50%, potentially rendering the drug ineffective at preventing clots.

Carbamazepine and phenytoin (antiepileptic drugs) are equally potent inducers. St. John's Wort, a commonly used herbal supplement for mood support, is also a strong CYP3A4 inducer and should never be combined with rivaroxaban. The consequence of using rivaroxaban with these inducers is thromboembolism—clot formation despite anticoagulant therapy.

3. Other Anticoagulants: Warfarin and Enoxaparin

Rivaroxaban should never be combined with other anticoagulants unless there is a specific clinical reason approved by the prescribing physician. Warfarin (an older vitamin K antagonist) and enoxaparin (a low-molecular-weight heparin used for acute clot prevention) both increase bleeding risk independently. Adding rivaroxaban stacks the anticoagulant effect, creating an uncontrollable bleeding hazard.

The FDA labeling clearly states that concurrent use is contraindicated unless the benefits outweigh the risks—a determination only a physician caring for that specific patient can make, typically in exceptional transitional scenarios (like bridging from one anticoagulant to another during a short overlap period).

Major Interactions Requiring Close Monitoring

SSRIs, SNRIs, and Serotonergic Drugs (Including Trazodone)

Selective serotonin reuptake inhibitors (SSRIs like sertraline and paroxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs like venlafaxine) increase bleeding risk when combined with anticoagulants. The mechanism is not metabolic (these drugs do not significantly inhibit CYP3A4) but rather pharmacodynamic: serotonin is involved in platelet aggregation and hemostasis. By raising serotonin, these drugs impair platelet function and increase bleeding risk on top of rivaroxaban's anticoagulant effect.

Trazodone hydrochloride, a sedating antidepressant, carries the same serotonergic bleeding risk. Patients on rivaroxaban who require an antidepressant should discuss this interaction with their cardiologist. The benefit of treating depression may outweigh the increased bleeding risk, but the combination requires informed consent and awareness of bleeding warning signs.

NSAIDs and Antiplatelet Agents

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen inhibit platelet function and irritate the gastrointestinal mucosa, increasing both bleeding tendency and GI ulcer risk. When combined with rivaroxaban, they significantly raise the bleeding hazard. Aspirin, while sometimes intentionally co-prescribed with rivaroxaban in certain acute coronary syndrome scenarios, must be done under physician supervision.

If a patient on rivaroxaban needs pain relief, acetaminophen is preferred. If NSAIDs are truly necessary, the lowest effective dose for the shortest duration should be used, and gastroprotection (proton pump inhibitor) should be considered.

Potent CYP3A4 Inhibitors (Moderate Severity)

While not necessarily contraindicated, several moderate-to-strong CYP3A4 inhibitors warrant caution. These include certain protease inhibitors used in HIV treatment (aside from ritonavir), some antifungals (fluconazole is weaker than ketoconazole but still significant), and drugs like diltiazem and verapamil (calcium channel blockers used for hypertension and heart rate control).

In these cases, dose adjustment of rivaroxaban may be warranted. The standard rivaroxaban dose for atrial fibrillation is 20 mg once daily (10 mg if renal impairment exists). In the presence of moderate CYP3A4 inhibition, some clinicians reduce this to 15 mg daily or implement enhanced monitoring for bleeding signs.

Clinical Scenario 1: The Atrial Fibrillation Patient With a Fungal Infection

A 68-year-old woman with paroxysmal atrial fibrillation has been stable on rivaroxaban 20 mg daily for 18 months. She presents to her primary care physician with symptoms of vaginal candidiasis and is prescribed ketoconazole 200 mg twice daily for 14 days. Without checking for drug interactions, she begins taking both medications concurrently.

Within 5 days, she develops unexplained bruising on her arms and legs. Three days later, she has a nosebleed that doesn't stop for 20 minutes. She calls her cardiologist, who immediately asks whether she started any new medications. Upon learning about the ketoconazole, the cardiologist instructs her to stop ketoconazole immediately and switch to a topical antifungal (miconazole cream), which has minimal systemic absorption and negligible CYP3A4 interaction.

The key lesson: ketoconazole increased rivaroxaban blood levels substantially, causing supratherapeutic anticoagulation and bleeding. Had the patient or pharmacy flagged this interaction at the time of ketoconazole dispensing, the adverse event would have been prevented. This scenario—published in case reports within the FDA Adverse Event Reporting System (FAERS)—illustrates why vigilance is essential.

Clinical Scenario 2: The Tuberculosis Patient Requiring Anticoagulation

A 52-year-old man with a history of pulmonary tuberculosis was recently hospitalized with a acute PE and started on rivaroxaban 15 mg daily (dose-reduced due to acute illness). Six weeks later, he develops a recurrent pulmonary tuberculosis infection and is prescribed rifampin 600 mg daily as part of standard TB therapy.

His infectious disease physician is aware of the interaction and coordinates with cardiology. They decide that stopping rivaroxaban is too risky (PE recurrence could be fatal), but they recognize that rifampin will substantially reduce rivaroxaban levels. The team makes an informed decision to increase rivaroxaban to 20 mg daily and implement close clinical surveillance for signs of PE recurrence (shortness of breath, chest pain, leg swelling). Additionally, they plan repeat CT pulmonary angiography (CTPA) at 3 months to confirm the clot has not recurred.

This scenario—also documented in clinical literature—shows how contraindicated interactions are sometimes necessary to navigate when the clinical benefits outweigh risks. However, this decision requires expert physician coordination, not patient self-management. A patient should never increase or adjust their rivaroxaban dose without explicit instruction from their prescriber.

Comprehensive List of Top Rivaroxaban Interactions

The following drugs carry major or contraindicated interactions with rivaroxaban:

• Ketoconazole (and itraconazole, voriconazole): Contraindicated. Azole antifungals inhibit CYP3A4 and P-gp, increasing rivaroxaban exposure up to 160%. Risk of serious bleeding.
• Ritonavir: Contraindicated. Potent dual CYP3A4/P-gp inhibitor used in HIV therapy. Dramatically increases rivaroxaban levels.
• Rifampin: Contraindicated. TB antibiotic. Strong dual CYP3A4/P-gp inducer decreases rivaroxaban exposure ~50%, risking clot formation.
• Carbamazepine: Contraindicated. Antiepileptic. Strong inducer significantly reduces rivaroxaban effectiveness.
• Phenytoin: Contraindicated. Antiepileptic. Strong inducer similar to carbamazepine; avoid concurrent use.
• St. John's Wort: Contraindicated. Herbal supplement. CYP3A4 inducer reduces rivaroxaban levels and efficacy.
• Warfarin: Contraindicated unless bridging. Other anticoagulant. Combined anticoagulant effect increases bleeding risk uncontrollably.
• Enoxaparin: Contraindicated unless bridging. LMWH anticoagulant. Do not use concurrently with rivaroxaban outside of supervised transitions.
• Trazodone: Major interaction. Serotonergic antidepressant impairs platelet function; increased bleeding risk. Use requires careful monitoring.
• SSRIs and SNRIs (sertraline, paroxetine, venlafaxine, fluoxetine, escitalopram): Major interaction. Serotonin effects reduce platelet aggregation. Increased bleeding risk; benefit-risk assessment needed.
• NSAIDs (ibuprofen, naproxen, indomethacin): Major interaction. Platelet inhibition and GI ulceration increase bleeding. Use lowest dose, shortest duration, or choose acetaminophen instead.
• Clarithromycin: Major interaction. Macrolide antibiotic; moderate CYP3A4 inhibitor. Increases rivaroxaban levels. Consider alternatives like azithromycin or non-macrolide antibiotics.
• Diltiazem and Verapamil: Moderate interaction. Calcium channel blockers inhibit CYP3A4. May increase rivaroxaban levels; monitor for bleeding.

What Patients Should Tell Their Doctor and Pharmacist

Before starting rivaroxaban or whenever a new medication is prescribed, patients should proactively communicate the following:

• All current medications, including over-the-counter drugs and supplements
• Herbal products (especially St. John's Wort for mood, ginkgo biloba, garlic supplements, or other "natural" anticoagulants)
• Any history of liver disease or reduced kidney function (both affect rivaroxaban levels)
• Any previous bleeding episodes or clotting events
• Pregnancy status or plans to become pregnant (rivaroxaban is generally contraindicated in pregnancy)
• Alcohol use (alcohol impairs hemostasis and increases bleeding with rivaroxaban)
• Any scheduled surgery or dental procedures

Patients should also ask their pharmacist to check for interactions every time a new prescription is filled. At checkdruginteractions.com, you can enter your complete medication list and receive real-time alerts about potentially serious combinations before they cause harm.

Management Strategies and Clinical Adjustments

If a Contraindicated Drug Is Necessary

In rare cases where a contraindicated drug is medically necessary (e.g., a TB patient requiring rifampin or a cancer patient requiring a protease inhibitor), a physician may:

• Increase the rivaroxaban dose (from 20 mg to 30 mg daily in non-renal impairment scenarios, if using an inducer)
• Switch to an alternative anticoagulant not metabolized by CYP3A4 (e.g., apixaban, which relies less on CYP3A4, though this is not ideal for all scenarios)
• Implement enhanced monitoring for thromboembolism (clinical signs, imaging) or bleeding
• Limit the duration of the contraindicated drug if possible
• Use temporary alternative therapies (e.g., topical antifungals instead of systemic ketoconazole)

If a Major Interaction Is Present

For major interactions like SSRIs or NSAIDs:

• Quantify the benefit: Does the patient truly need this medication, or are alternatives available?
• Patient counseling: Educate the patient on bleeding warning signs (easy bruising, nosebleeds, blood in urine/stool, severe headache, shortness of breath)
• Monitoring: Schedule follow-up visits to assess for bleeding complications
• Dose adjustment: If using a moderate CYP3A4 inhibitor with rivaroxaban, consider reducing rivaroxaban by 25–50%
• Gastroprotection: If NSAIDs are essential, add a proton pump inhibitor (omeprazole or pantoprazole) to reduce GI bleeding risk

Key Takeaways

• Rivaroxaban is metabolized via CYP3A4 and P-glycoprotein. Any drug that inhibits or induces these pathways will change rivaroxaban blood levels, potentially causing dangerous bleeding (if levels are too high) or clotting (if levels are too low).
• Contraindicated interactions—ketoconazole, rifampin, warfarin, enoxaparin, and others—should be avoided entirely unless a physician explicitly approves an exception with full informed consent and enhanced monitoring.
• Major interactions with SSRIs, NSAIDs, and serotonergic drugs increase bleeding risk and require careful benefit-risk assessment and patient education about warning signs.
• Always inform your doctor and pharmacist of every medication, supplement, and herbal product before starting rivaroxaban or adding new prescriptions. Use a comprehensive drug interaction checker to verify safety.
• Never adjust your rivaroxaban dose or stop the medication without explicit instruction from your prescriber. Stopping rivaroxaban without guidance can lead to PE or stroke; increasing it can cause life-threatening bleeding.

Sources

• FDA Drug Labeling for Rivaroxaban (Xarelto): FDA Drug Labeling via OpenFDA (open.fda.gov) — Search "rivaroxaban" for full prescribing information including contraindications and drug interactions.
• Patel MR, Mahaffey KW, Garg J, et al. (ROCKET AF Investigators). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. PubMed PMID: 21830957.
• FDA Adverse Event Reporting System (FAERS): FDA FAERS Public Dashboard — Search for rivaroxaban adverse events linked to drug interactions and bleeding complications.
• National Institutes of Health, National Library of Medicine: PubChem — Database of rivaroxaban metabolism and CYP3A4 interactions.
• Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in mice, rats, and dogs. Drug Metab Dispos. 2009;37(5):1056-1064. PubMed PMID: 19197976.
• Lindhoff-Last E, Samama MM, Ortel TL. Assays for measuring rivaroxaban: a review. J Thromb Thrombolysis. 2016;41(3):412-423. PubMed PMID: 26547104.

Don't Navigate Rivaroxaban Interactions Alone

Rivaroxaban is a powerful, effective anticoagulant, but its narrow therapeutic window and complex metabolic interactions demand vigilance. A single missed interaction can cause catastrophic bleeding or life-threatening clot formation. At checkdruginteractions.com, you can enter your complete medication list and receive instant, evidence-based alerts about every potential interaction with rivaroxaban and all your other drugs. Our database is powered by FDA drug labels and NIH data, updated continuously, and reviewed by pharmacists. Before you fill a prescription or start a new supplement, check your full medication profile at checkdruginteractions.com. Your life may depend on it.